€1.13
Your prediction
Description SELLAS Life Sciences
SELLAS Life Sciences is a clinical-stage biopharmaceutical company that specializes in the development of cancer immunotherapies. The company's lead product candidate, galinpepimut-S (GPS), is a peptide-based immunotherapy that targets a specific protein found in various cancers, including acute myeloid leukemia, malignant pleural mesothelioma, and multiple myeloma.
SELLAS also has a second product candidate, nelipepimut-S (NPS), which is a cancer vaccine designed to activate the immune system against tumors that express the HER2/neu oncogene. The vaccine has shown promise in early-stage clinical trials for the treatment of breast cancer.
SELLAS is listed on the NASDAQ Global Market under the symbol RXII, and as of April 2021, had a market capitalization of approximately $67 million.
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for SELLAS Life Sciences
sharewise wants to provide you with the best news and tools for SELLAS Life Sciences, so we directly link to the best financial data sources.